Budget impact analysis of biosimilar infliximab (CT-P13 ...

(laboratory test, rheumatology visits, X-ray, cardiology and pulmonology monitoring). The model accounted for those biological agents that are reimbursed in a given country for the treatment of RA (Table 2). Drug acquisition costs were derived from official national price lists in each country. We used retail prices for the analysis. ................
................